con's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2012, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
Lexicon Pharmaceuticals, Inc.
Selected Financial DataConsolidated Statements of Operations DataThree Months EndedJune 30,Six Months EndedJune 30,(In thousands, except per share data)2013201220132012(unaudited)(unaudited)Revenues:Collaborative research$
351Subscription and license fees3-79148Total revenues214199574499Operating expenses:Research and development, including stock-based compensation of $1,022, $915, $2,352 and $1,952, respectively23,69219,35544,01942,392Increase in fair value of Symphony Icon, Inc. purchase liability4772,1621,7414,243General and administrative, including stock-based compensation of $847, $680, $1,626 and $1,361, respectively4,6694,1628,9938,727Total operating expenses28,83825,67954,75355,362Loss from operations(28,624)(25,480)(54,179)(54,863)Interest income445897114Interest expense(496)(530)(1,002)(1,067)Other income (expense), net(4)213017Consolidated net loss$
(55,799)Consolidated net loss per common share, basic and diluted$ (0.06)$ (0.05)$ (0.11)$ (0.12)Shares used in computing net loss attributable to Lexicon Pharmaceuticals, Inc. per common share, basic and diluted513,083480,634512,757480,479 Consolidated Balance Sheet DataAs of June 30,As of December 31,(In thousands)20132012(unaudited)Cash and investments
223,208Property and equipment, net
Page: 1 2 3 4 5 6 7 Related medicine technology :1
|SOURCE Lexicon Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved
. Lexicon to Report Second Quarter Financial Results on July 30, 20132
. Lexicon Presents Data at the American Diabetes Association Meeting On Blood Pressure Reduction and Weight Loss In Clinical Trial of LX42113
. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract4
. Lexicon To Present At The Goldman Sachs Global Healthcare Conference5
. Lexicon To Present At The Jefferies Global Healthcare Conference6
. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference7
. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2013 First Quarter Financial Results8
. Lexicon Advances LX4211 In Type 1 Diabetes Phase 2 Trial9
. Lexicon to Report First Quarter Financial Results on May 10, 201310
. Lexicon To Present At The Needham Healthcare Conference11
. Lexicon Pharmaceuticals Provides Clinical Pipeline Update And Reports 2012 Fourth Quarter And Full Year Financial Results